icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
MRcy2qn5rnRuw6NF